Condition: Fibrodysplasia Ossificans Progressiva (FOP) · Sponsor: Incyte Corporation
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP).
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| Children'S Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Penn Medicine - Perelman Center For Advanced Medicine | Philadelphia, Pennsylvania, United States | Active Not Recruiting |
| Hospital Italiano de Buenos Aires | Buenos Aires, Argentina | Active Not Recruiting |
| Royal North Shore Hospital | St Leonards, New South Wales, Australia | Completed |
| Murdoch Children'S Research Institute | Parkville, Victoria, Australia | Active Not Recruiting |
| Albert Einstein Israelite Hospital | São Paulo, Brazil | Active Not Recruiting |
| University Health Network Toronto General Hospital | Toronto, Ontario, Canada | Active Not Recruiting |
| Centro de Estudios Reumatologicos | Santiago, Chile | Active Not Recruiting |
| Beijing Childrens Hospital Capital Medical University | Beijing, China | Recruiting |
| Tongji Hospital of Tongji University | Shanghai, China | Recruiting |
| Shanghai Childrens Medical Center | Shanghai, China | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05090891